4:44 PM
 | 
Aug 31, 2012
 |  BC Extra  |  Company News

VLST in-licenses Pfizer's anti-CD40 mAb

Pfizer Inc. (NYSE:PFE) granted VLST Corp. (Seattle, Wash.) worldwide rights to cancer compound CP-870,893. The anti- CD40 mAb has completed five Phase I trials. VLST expects to start additional Phase I testing in about 6-9 months to confirm dosing...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >